OptiNose, Inc. (NASDAQ:OPTN) faces a pessimistic outlook from investment analysts with a target price significantly lower than its market price.
Collegium Pharmaceutical, Inc. (COLL) is perceived as overvalued by 41.93%, despite a positive EPS of $1.86 and a PE ratio of 13.36.
Alkermes plc (ALKS) appears slightly undervalued with an EPS of $2.20 and a PE ratio of 12.96, indicating the highest growth potential among the compared companies.
OptiNose, Inc. (NASDAQ:OPTN) is a pharmaceutical company that focuses on developing and commercializing products for patients with ear, nose, and throat (ENT) disorders. Despite its innovative approach, OPTN is currently not favored by investment analysts due to its target price being significantly lower than its market price. This suggests a pessimistic outlook for the company’s stock performance.
In comparison, Collegium Pharmaceutical, Inc. (COLL) is trading at $29.93, with a DCF value of $17.38. This indicates that the stock is overvalued by 41.93%. Despite having a positive EPS of $1.86 and a PE ratio of 13.36, the market cap stands at $942.36 million, reflecting a cautious investor sentiment.
Alkermes plc (ALKS) presents a more optimistic scenario. With a current stock price of $33.92 and a DCF value of $34.32, ALKS shows a slight undervaluation of 1.18%. This, coupled with an EPS of $2.20 and a PE ratio of 12.96, suggests that ALKS has the highest growth potential among its peers, as highlighted by its market cap of $5.52 billion.
Deciphera Pharmaceuticals, Inc. (DCPH) is another peer, with a stock price of $25.59 and a DCF value of $17.21, indicating an overvaluation of 32.74%. The company has a negative EPS of -$2.21 and a negative PE ratio of -7.04, which may concern investors despite its market cap of $2.21 billion.
